Ravi A. Madan, MD, discusses the potential impact of docetaxel, abiraterone acetate, androgen deprivation therapy, and radiotherapy on patients with metastatic castration-sensitive prostate cancer.
At the 2021 European Society for Medical Oncology Annual Congress, CancerNetwork® spoke with Ravi A. Madan, MD, clinical director of the genitourinary malignancies branch at the Center for Cancer Research, National Cancer Institute, about the significance of the phase 3 PEACE-1 trial (NCT01957436) with docetaxel, abiraterone acetate (Zytiga), androgen deprivation therapy (ADT), and radiotherapy for the treatment of metastatic castration-sensitive prostate cancer (mCSPC).
Madan explained how the study’s regimen yielded promising data and may lead to superior outcomes in patients with mCSPC. However, he explained that investigators will need to ensure that the regimen is feasible so more patients are able to receive benefit from treatment.
[At] this year’s meeting, we had some very interesting data presented in the PEACE-1 trial that highlighted the potential of docetaxel and abiraterone in combination with ADT, and potentially radiation, to have superior outcomes in [mCSPC]. This represents the first data that have shown that combination of chemotherapy and an anti-androgen like abiraterone can improve outcomes [in this setting]. We have to figure out how we can get those data to our patients and make it feasible for more people to benefit.
Fizazi K, Galceran JC, Foulon S, et al. A phase III trial with a 2x2 factorial design in men with de novo metastatic castration-sensitive prostate cancer: Overall survival with abiraterone acetate plus prednisone in PEACE-1. Ann Oncol. 2021;32(suppl 5):S1283-S1346. doi:10.1016/annonc/annonc741